Holen Sie sich die Stockscreener-App
3.86
4.46%
-0.18
Handel nachbörslich:
3.88
0.02
+0.52%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.04
Offen:
$4.08
24-Stunden-Volumen:
11.01M
Relative Volume:
1.60
Marktkapitalisierung:
$549.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.34M
KGV:
-2.8382
EPS:
-1.36
Netto-Cashflow:
$-36.91M
1W Leistung:
+2.39%
1M Leistung:
+112.09%
6M Leistung:
+84.69%
1J Leistung:
+306.14%
1-Tages-Spanne:
$3.64
$4.13
1-Wochen-Bereich:
$3.62
$5.1765
52-Wochen-Spanne:
$0.8505
$5.1765
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Firmenname
Sellas Life Sciences Group Inc
Sektor
Branche
Telefon
(646) 200-5278
Adresse
7 TIMES SQUARE, NEW YORK, NY
Vergleichen Sie SLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
3.86 | 575.47M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-07-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-01 | Eingeleitet | Oppenheimer | Outperform |
| 2018-04-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Hochstufung | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech - GlobeNewswire
How interest rate cuts could boost SELLAS Life Sciences Group Inc. stockJuly 2025 Earnings & AI Optimized Trading Strategy Guides - ulpravda.ru
Best Penny Stocks To Follow TodayJanuary 4th - MarketBeat
SLS Stock Breaches $5 Level After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B - Asianet Newsable
Penny Stocks To Follow TodayJanuary 3rd - MarketBeat
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
A Look At SELLAS Life Sciences Group (SLS) Valuation As REGAL Phase 3 Trial Nears Final Event Trigger - simplywall.st
SELLAS Life Sciences Group (SLS) Is Up 50.8% After REGAL Trial Nears Final OS TriggerHas The Bull Case Changed? - Yahoo Finance
SELLAS Life Sciences (ASX:SLS) Shares Flat After Phase 3 Update - Kalkine Media
Is the Event-Driven REGAL Trial Timeline Reframing SELLAS Life Sciences Group’s (SLS) Risk-Reward Profile? - simplywall.st
Promising Penny Stocks To Add to Your WatchlistJanuary 1st - MarketBeat
SELLAS Life Sciences Stock Surges as Phase 3 Trial Nears Data Trigger - StocksToTrade
Why Is SLS Stock Drawing Significant Investor Attention Today? - Asianet Newsable
Ironwood Pharmaceuticals, Baidu, Vertiv Holdings And Other Big Stocks Moving Higher On Friday - Benzinga
SELLAS Life Sciences Group Stock (SLS) Opinions on Phase 3 Trial Progress - Quiver Quantitative
SELLAS Life Sciences Group stock soars as it nears final analysis in cancer study - MSN
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews
SELLAS (SLS) stock jumps about 10% in premarket as REGAL AML trial milestone stays in focus - ts2.tech
Sellas Life Sciences Showcases Promising Phase 2 Data at Annual Meeting - StocksToTrade
Sellas Life Sciences Showcases Breakthroughs in AML Treatment - timothysykes.com
Axsome Therapeutics, Plug Power And Other Big Stocks Moving Higher On Wednesday - Benzinga
Largest borrow rate increases among liquid names - TipRanks
SELLAS Life Sciences Stock Surge: Buy or Wait? - StocksToTrade
SELLAS’s Therapy Triumph: Market Buzz - timothysykes.com
Discover the Top 5 Small-Cap Biotech Stocks in 2025 - Investing News Network
CapsoVision, ACM Research And Other Big Stocks Moving Higher On Tuesday - Benzinga
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia - MarketScreener
SELLAS Reports Continued Progress In Phase 3 REGAL Trial Of GPS In Acute Myeloid Leukemia - Nasdaq
SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next - ts2.tech
Sellas Life Sciences Stock Surges After Positive Clinical Trials - StocksToTrade
SELLAS Life Sciences Stock Is Surging Higher: What's Going On? - Benzinga
Sellas Life Sciences stock soars after trial update shows slower event rate - Investing.com Nigeria
Sellas Life Sciences stock soars after trial update shows slower event rate By Investing.com - Investing.com South Africa
SELLAS Life Sciences (SLS) Stock: Shows Bullish Momentum Ahead of Pivotal AML Data Readout - parameter.io
Finanzdaten der Sellas Life Sciences Group Inc-Aktie (SLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):